These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31976328)

  • 1. Dihydroartemisinin Sensitizes Mutant p53 (R248Q)-Expressing Hepatocellular Carcinoma Cells to Doxorubicin by Inhibiting P-gp Expression.
    Yang Y; He J; Chen J; Lin L; Liu Y; Zhou C; Su Y; Wei H
    Biomed Res Int; 2019; 2019():8207056. PubMed ID: 31976328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line.
    Chan KT; Lung ML
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):519-26. PubMed ID: 15004724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
    Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
    Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1.
    Lu L; Zhang D; Xu Y; Bai G; Lv Y; Liang J
    Biomed Pharmacother; 2018 Aug; 104():613-621. PubMed ID: 29803174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells.
    Yan F; Wang XM; Pan C; Ma QM
    World J Gastroenterol; 2009 Mar; 15(12):1443-51. PubMed ID: 19322916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
    Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
    Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib.
    Hou C; Guo D; Yu X; Wang S; Liu T
    Biomed Pharmacother; 2020 Jun; 126():109862. PubMed ID: 32120157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGF reverses multi-drug resistance via the p-ERK pathway in HepG2/ADM and SMMC7721/ADM hepatocellular carcinoma models.
    Yan F; Bai LP; Gao H; Zhu CM; Lin L; Kang XP
    Asian Pac J Cancer Prev; 2014; 15(6):2619-23. PubMed ID: 24761873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 and oxaliplatin via p53-independent pathway in vitro and in vivo.
    Liu X; Xu J; Wang S; Yu X; Kou B; Chai M; Zang Y; Chen D
    Int J Oncol; 2017 Oct; 51(4):1291-1299. PubMed ID: 28902369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-215 is upregulated by treatment with Adriamycin and leads to the chemoresistance of hepatocellular carcinoma cells and tissues.
    Wang L; Wang YM; Xu S; Wang WG; Chen Y; Mao JY; Tian BL
    Mol Med Rep; 2015 Oct; 12(4):5274-80. PubMed ID: 26135967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism.
    Giovannini C; Gramantieri L; Chieco P; Minguzzi M; Lago F; Pianetti S; Ramazzotti E; Marcu KB; Bolondi L
    J Hepatol; 2009 May; 50(5):969-79. PubMed ID: 19304334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Mediates the Reversal Effect of Verapamil on Chemo-Resistance to Adriamycin of Hepatocellular Carcinoma.
    Yang G; Fan G; Zhang T; Ma K; Huang J; Liu M; Teng X; Xu K; Fan P; Cheng D
    Med Sci Monit; 2018 Apr; 24():2072-2082. PubMed ID: 29627846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ginkgo biloba Extract Mechanism Inhibits Hepatocellular Carcinoma through the Nuclear Factor-κB/p53 Signaling Pathway.
    Wang R; Shao X; Yang J; Liu Z; Chew L; Shao Y
    J Environ Pathol Toxicol Oncol; 2020; 39(2):179-189. PubMed ID: 32749126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway.
    Gao AM; Ke ZP; Wang JN; Yang JY; Chen SY; Chen H
    Carcinogenesis; 2013 Aug; 34(8):1806-14. PubMed ID: 23563091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma and chemotherapy: the role of p53.
    Brito AF; Abrantes AM; Pinto-Costa C; Gomes AR; Mamede AC; Casalta-Lopes J; Gonçalves AC; Sarmento-Ribeiro AB; Tralhão JG; Botelho MF
    Chemotherapy; 2012; 58(5):381-6. PubMed ID: 23257706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma.
    Huo X; Zhang Q; Liu AM; Tang C; Gong Y; Bian J; Luk JM; Xu Z; Chen J
    Oncol Rep; 2013 Feb; 29(2):840-6. PubMed ID: 23232767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
    Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
    J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.
    Shi H; Lambert JM; Hautefeuille A; Bykov VJ; Wiman KG; Hainaut P; Caron de Fromentel C
    Carcinogenesis; 2008 Jul; 29(7):1428-34. PubMed ID: 18048389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
    Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
    Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZD3759 induces apoptosis in hepatoma cells by activating a p53-SMAD4 positive feedback loop.
    Chao D; Pang L; Shi Y; Wang W; Liu K
    Biochem Biophys Res Commun; 2019 Feb; 509(2):535-540. PubMed ID: 30598263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.